Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of 3B Pharmaceuticals.

    Client Virtual Booth

    3B PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    3B Pharmaceuticals
    Germany Flag
    Country
    Country
    Germany
    Address
    Address
    Represented by its managing director Dr. Ulrich Reineke Magnusstraße 11 D-12489 Berlin
    Telephone
    Telephone
    +49 (0)30 / 63 92 - 43 17
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://3b-pharma.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic an...

    Details:

    Under the agreement, RefleXion to develop and commercialize a specific 3BP molecule, RXM-4768 which targets fibroblast activation protein (FAP) found in nearly all solid tumor types, to direct its SCINTIX™ biology-guided radiotherapy.


    Lead Product(s): RXM-4768

    Therapeutic Area: Oncology Product Name: RXM-4768

    Highest Development Status: PreclinicalProduct Type: Peptide

    Partner/Sponsor/Collaborator: RefleXion Medical

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement September 20, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    3B Pharmaceuticals Enters Into a Global Exclusive Licensing Agreement for Its FAP-Targeting Peptide Technology

    Details:

    The agreement gives Novartis exclusive worldwide rights to develop and commercialize therapeutic and imaging applications for 3BP's FAP-targeting peptide technology, including FAP-2286.


    Lead Product(s): FAP-2286

    Therapeutic Area: Technology Product Name: FAP-2286

    Highest Development Status: Discovery PlatformProduct Type: Peptide

    Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

    Deal Size: $465.0 million Upfront Cash: $40.0 million

    Deal Type: Licensing Agreement April 24, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Clovis Oncology Submits IND for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial

    Details:

    Following clearance of the INDs by FDA, Clovis plans to initiate a Phase 1/2 clinical trial of lutetium-177 labeled FAP-2286 to determine the dose and tolerability of the FAP-targeting therapeutic agent, with expansion cohorts planned in multiple tumor types.


    Lead Product(s): 177Lu-FAP-2286

    Therapeutic Area: Oncology Product Name: 177Lu-FAP-2286

    Highest Development Status: IND EnablingProduct Type: Peptide

    Recipient: Clovis Oncology

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 29, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-Licensing Agreement

    Details:

    This agreement extends the radio-oncology portfolio of Debiopharm which currently includes another clinical stage radiotherapeutic and the radiotherapyenhancing antagonist of IAPs.


    Lead Product(s): Debio 0228

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Debiopharm

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement March 25, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search